If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bump
IMO, you wouldn't need to increase the dose, if anything a reduction of the dose could be allowed for therefore decreasing the cost of the chemotherapy, as the dose doesn't need to travel through the body and be diluted to get to the tumour, it is targeted to that tumour/ tumour cells. Think of chemotherapy as a nuclear bomb, which effects the whole body, precision is like a drone strike, targeted. All IMO DYOR.
Here is some more on the pre|CISION chemotherapy:
The targets for the future Affimer pre|CISION chemotherapy
Avacta has so much potential in this particular area.
The first is AVA6000 Pro-doxorubicin, Doxorubicin has been a standard of care treatment for advanced soft tissue sarcoma (ASTS) for 40 years. Treatment is currently limited to six cycles due to cumulative cardio-toxicity. However, the global market for this generic drug is still $1bn. AVA6000 Market Opportunity for three opportunities ASTS, breast and ovarian cancer, with peak sales for a safer and more efficacious form of dox in the US/EU alone is estimated to be $1.5bn pa with a 5-10% royalty to Avacta plus development milestones in the near term. This is an incredible prospect!
But then the opportunities to use the recent funds to develop the additional pipeline of pre|CISION pro-drugs, some of which have already been synthesized, with an addressable market of many $billions per year.
Including these drugs but not limited to:
• preCISION Velcade
• preCISION Paclitaxel
• preCISION Oxaliplatin
• preCISION Gemcitabine
• preCISION Capecitabine
• preCISION PARP inhibitor
• preCISION PD-1 Inhibitor
• preCISION AKT inhibitor
• preCISION Balixafortide
The combination of Avacta’s two proprietary platforms to deliver chemotherapy and immunotherapy in a single drug molecule has two key points:
The "warhead"
Released in the tumour by the preCISION linker chemistry.
• Selected to kill tumour cells and create an inflammatory event that recruits the immune system.
• Potential for a pipeline of TMACs using different immuno-active warheads
Then the Affimer Immunotherapy:
• Supports the immune attack on the tumour by blocking the signal the tumour uses to evade the immune system.
• Potential of a pipeline of immunotherapy and targeting Affimers including bispecifics
If the trials are successful with AVA6000 the developments in these other treatments will surely be accelerated. Within 2 to 3 years we could see the results of these developments being used in Oncology clinics around world saving lives.
This area has massive potential!
Cheers Rich
And the same platform technology could potentially used with other toxic chemotherapy drugs to increase the dose significantly and the effectiveness of the treatment.
Not sure that's quite right Gunnerbgood - I think they showed that they could raise the dose to 18 times the current level before they hit the same levels of cardiotoxity that they have today with the current therapies, but in practice they wouldn't use that dose because even at that level, there is some damage to the heart and you can only have four or five cycles before you have to stop completely. I think AS said in the Proactive Investors video that they would probably keep the dose at the same level as they use today, because at that level there is little or no cardiotoxicity and therefore you can have as many cycles as are needed to eradicate the tumour. Presumably there may also be an option somewhere in the middle, where you could zap (I think that's the technical term) the tumour harder but still not damage healthy tissue. Either way, it's a lifesaver.
Cheers gunnerbegood
Yes in a previous webinar and in presentation slides they can administer 18x the drug with only the same side effects of 1x that administration normally
Yes, slide 12... It’s the most amazing bar chart I’ve ever seen. When I first saw this the only thing I could say, and I did, out loud and I’m not one for that kind of thing, was... wow. It’s incredible and I dearly hope the trials go well and it becomes a reality.
https://avacta.com/wp-content/uploads/2020/06/Placing-Presentation-June-2020-1.pdf
Richken,
A question if I may, or anybody for that matter,
Having watched the video today from AS, He mentioned a little about the cancer treatment and having the capabilities of directing the chemo directly into the Tumor without to many side affects if any at all.
Have I seen somewhere, that by doing this they can administer a stronger doseage into the Tumour, without the horrible sideaffects ?
*to do
Avacta is on a clear path to get taken out.
The don't need to anything else than keep ticking the boxes.
#LongAndStrong
The question is when and will the numbers not only exceed the positive position that Sons have, but be available at speed to a greater global customer base.
The sure point is the would needs accurate and fast testing and with a global population heading towards 8 billion people there is a market for all.
Our hears will stop if we get suspended for a pending announcement. It goes to show the expectations attached to truly exceptional tests.
Avacta cant be too far behind.
Very exciting times are coming. But we have two types of test and the up and coming virus neutraliser! What will that be worth?
About time we had an RNS! Lull before the storm?
Maybe...
Anyone else a little excited!
Cheers Rich